ad now

loading...

media venus

Sunday 30 August 2020

ESC: AstraZeneca's Farxiga cuts kidney disease risks by 39% in trial that could 'rewrite' the treatment textbook - FiercePharma

ESC: AstraZeneca's Farxiga cuts kidney disease risks by 39% in trial that could 'rewrite' the treatment textbook  FiercePharmaView Full Coverage on Google News

from Business - Latest - Google News https://ift.tt/2YOit89

No comments:

Post a Comment